Generic drugmakers face pricing pressure, but companies like TEVA, SDZNY and RDY are betting on complex generics and biosimilars to protect growth.

March 6 (Reuters) - The global weight-loss drug market is entering a new phase, driven by the arrival of oral options, looming generic rivals and falling U.S. prices for blockbuster treatments from ...

The Inflation Reduction Act (IRA) represents a transformative shift in US health care policy by enabling Medicare to negotiate drug prices for high-expenditure medicatio ...

The global weight-loss drug market is entering a new phase, driven by the arrival of oral options, looming generic rivals and falling U.S. prices for blockbuster treatments from Eli Lilly and Novo ...

Amgen (NASDAQ:AMGN) executives highlighted broad-based commercial momentum, a focus on long-term growth drivers, and several ...

LVEF (Left Ventricular Ejection Fraction): Percentage measure of how much blood the left ventricle pumps out with each ...

Consumer protection experts warn that legal data collection by brokers poses greater privacy threats than traditional scams, ...

Explore the insights from Cenevo on the slow adoption of AI in drug discovery and the challenges faced by laboratories today.

As competition intensifies across the CFD brokerage and exchange landscape, VIP client retention is no longer just about ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...